Cytokines and their relationship to the symptoms and outcome of cancer

Bostjan Seruga, Haibo Zhang, Lori J. Bernstein and Ian F. Tannock

Abstract | Tumours contain immune cells and a network of pro- and anti-inflammatory cytokines, which collaborate in the development and progression of cancer. Cytokine profiles might prove to be prognostic. The systemic effects of pro-inflammatory cytokines are associated with fatigue, depression and cognitive impairment, and can affect quality of life before, during and after treatment. In people with advanced cancer, pro-inflammatory cytokines are additionally associated with anorexia and cachexia, pain, toxicity of treatment and resistance to treatment. However, physical activity might modify cytokine levels and decrease fatigue in patients with cancer, and might also improve their prognosis.

Cytokines are a heterogeneous group of soluble small polypeptides or glycoproteins, which exert pleiotropic and redundant effects that promote growth, differentiation and activation of normal cells. Cytokines can have either pro- or anti-inflammatory activity and immunosuppressive activity, depending on the microenvironment. Immune cells are the major source of cytokines but many human cells are capable of producing them (TABLE 1) and, importantly, their production acts as a means of communication between both cells and tissues.

In this Perspective we discuss the role of cytokines in causing symptoms that affect quality of life in people with cancer and the possible influence of cytokines on cancer outcome.

Cytokines and cancer development

Under normal conditions, an inflammatory response (BOX 1) is regulated by active mechanisms. Anti-inflammatory cytokines, such as interleukin 10 (IL10) and transforming growth factor β (TGFβ), are important in this process, as are soluble receptors that neutralize the activity of cytokines, such as soluble IL1 receptor type II (sIL1R2), and cytokine receptor antagonists, such as IL1RA. Although often overlooked, neuronal pathways and hormones (such as cortisol and adrenaline) also affect the immune response. Adrenal production of cortisol, a potent anti-inflammatory glucocorticoid, is regulated by the hypothalamic–pituitary–adrenal (HPA) axis. Disrupted HPA signalling resulting in altered release of glucocorticoid hormones, or disrupted glucocorticoid receptor function, might sustain inflammation. A disturbed balance between pro- and anti-inflammatory mechanisms leads to chronic immune activation and inflammation, as occurs often in people with cancer.

Clinical studies. Clinical and epidemiological studies have suggested a strong association between chronic local inflammation and some types of cancer, with inflammation often occurring in and around tumours. Prehn first reported in 1972 that immune cells promote tumour growth in an animal model, and it is now established that the tumour stroma includes inflammatory cells, such as M2 macrophages, dendritic cells and T-regulatory lymphocytes, that promote development and progression of cancer (FIG. 1).

The tumour microenvironment is rich in cytokines and other inflammatory mediators that influence immunosuppression, growth of cancer cells, tissue remodelling and angiogenesis. Immunosuppressive networks mediated by IL10 and TGFβ seem to inhibit cell-mediated immune responses against cancer cells. Moreover, the function of circulating T cells is often impaired in cancer. Clinical data show a decreased ratio of circulating T helper 1 (T(H)1) to cells to circulating T(H)2 cells and their associated cytokines in different cancer types and in
Cytokine gene polymorphism in human cytokines the data are inconsistent (see transcription and expression, but for many of cancer. The most common variations in the risk of developing symptoms related to diagnosis than in healthy controls.

Increased levels of circulating cytokines and their receptors (most often of the pro-inflammatory cytokine IL6) have been found in observational studies of patients with various types of cancer, both at diagnosis of the primary disease and in those with metastases, compared with healthy people and people with benign tumours (TABLE 2). There have been few studies of circulating levels of cytokines in people after primary treatment of cancer and in cancer survivors. In a longitudinal study of patients with kidney cancer, circulating levels of IL6 and IL10 at diagnosis were higher than in controls with benign kidney disease, and remained significantly higher 3 months after resection of the primary tumour. Preliminary data from our group indicate that circulating levels of several different pro- and anti-inflammatory cytokines are substantially higher in people without active breast or colorectal cancer up to 5 years after diagnosis than in healthy controls.

Polymorphisms. Human genetic variation can modulate the risk of developing a cancer, the risk of developing symptoms related to cancer and its treatment, and the outcome of cancer. The most common variations in the genome are single-nucleotide polymorphisms (SNPs). In human disease several SNPs in genes encoding cytokines have been associated with variations in the level of transcription and expression, but for many cytokines the data are inconsistent (see Cytokine gene polymorphism in human disease in Further information). In a systematic review of 161 meta-analyses and pooled analyses of SNPs in 99 candidate genes in 18 cancer sites, nearly one-third (98/344) of gene variants were significantly associated with cancer, including 6 cytokine gene variants. Other small studies indicate that SNPs in cytokine genes might be involved in the development of cancer (TABLE 3); however, such results are not always in agreement. Generally, candidate gene studies are considered to be informative but to have limitations, a lack of replication being the main concern in these relatively small studies.

Cytokines and the central nervous system

Macrophages in the brain, known as microglial cells, are an important source of pro-inflammatory cytokines, and are involved in the pathogenesis of various neurological diseases. Furthermore, inflammatory stimuli, including circulating cytokines, can reach the brain by several pathways and stimulate microglial cells to produce pro-inflammatory cytokines and other inflammatory mediators. The best example of the communication between peripheral cytokines and the brain is ‘sickness behaviour’, which is induced by peripheral infection and mediated by transiently expressed pro-inflammatory cytokines in the peripheral and in the brain. Similarly, peripherally produced cytokines in cancer may have a role in the development of psychobiological symptoms, such as fatigue and cognitive impairment.

Cytokines and symptoms in cancer patients

Cytokines and cancer treatment. The production and release of cytokines can be affected by the cancer itself and by different treatments. Some cytokines, including interferon α (IFNα) and IL2, have been used in cancer treatment, and their ability to cause fatigue, depression and other symptoms is well-described. Release of cytokines may mediate both the organ-confined and the systemic toxic symptoms that are associated with different types of cancer treatment such as radiation therapy, chemotherapy and hormonal therapy (FIG. 3).

Radiation therapy can lead to release of cytokines in various tissues, and cytokines are associated with the development of late radiation damage that can occur in irradiated normal tissues months or years after treatment. TGFβ has a crucial role in the initiation, development and persistence of radiation-induced fibrosis, and circulating levels of TGFβ predict radiation-induced lung damage. TGFβ (−509 T) allele is associated with increased circulating levels of TGFβ in women with early breast cancer or gynaecological cancers. Combined analysis of two studies of women with breast cancer showed that the 8% of women who were homozygous for the TGFβ (−509 T) variant allele had a 15-fold increase in risk of fibrosis following radiotherapy (TABLE 3). Cytokines might also have systemic effects after radiation treatment. Evidence from animal models suggests that local irradiation of a tumour can result in regression of distant non-irradiated tumours, an effect that is mediated by T cells following systemic activation of the immune system.

Chemotherapy is also known to have direct and indirect effects on the immune system. Chemotherapy-induced death of cancer cells can cause the release of immunogenic antigens, which result in a cell-mediated immune response to the tumour, as recently reviewed by Zitvogel et al. Cytokine secretion induced by chemotherapeutic drugs might also mediate the development of other side effects, including psychobiological effects, during and after treatment (FIG. 3). Paclitaxel can mimic the effects of lipopolysaccharide (LPS), which is a ligand for Toll-like receptor 4 (TLR4) expressed on innate immune cells. Exposure of murine macrophages to paclitaxel led to the increased release of both tumour necrosis factor α (TNFα) and IL1β. Furthermore, paclitaxel can induce expression of the pro-inflammatory cytokine IL8 in lung carcinoma cell lines. Treatment with paclitaxel or docetaxel was reported to increase the expression of IL2,

Table 1 | Cytokines, immunity and inflammation

<table>
<thead>
<tr>
<th>Activity</th>
<th>Cytokines and receptors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cell-mediated immunity (pro-inflammatory)</td>
<td>IL1, IL2, IL4, IL6, IL7, IL10, IL11, IL12, IL15, IL16, IL17, IL18, IL21, IL23, TNFα, TNFβ, IFNα, IFNβ, IFNγ</td>
</tr>
<tr>
<td>Humoral immunity (pro-inflammatory)</td>
<td>IL1, IL2, IL4, IL5, IL6, IL10, IL12, IL13, IL15, IL21, IL25, TGFβ</td>
</tr>
<tr>
<td>Allergic immunity (pro-inflammatory)</td>
<td>IL3, IL4, IL5, IL9, IL13, IL25, IFNγ, GM-CSF, SCF</td>
</tr>
<tr>
<td>Anti-inflammatory</td>
<td>IL4, IL5, IL6, IL10, IL11, IL19, IL20, IL22, IL24, IL26, TGFβ, IL1RA, signalling by IL1RII</td>
</tr>
</tbody>
</table>

Pro-inflammatory cytokines stimulate cell-mediated, humoral and/or allergic immunity. The major cytokine mediating cell-mediated immunity is interferon-γ (IFNγ). Humoral immunity is mediated by B cells and production of antibodies; interleukin 4 (IL4), IL10, IL13 and transforming growth factor-β (TGFβ) trigger isotype switching of antibodies. Some cytokines have predominantly anti-inflammatory and immunosuppressive effects (for example, IL10 and TGFβ) or both pro- and anti-inflammatory effects (for example, IL6). Innate immune cells are the major source of IL1, IL6 and tumour necrosis factor-α (TNFα), which direct activity of adaptive immunity and inflammation. GM-CSF, granulocyte macrophage-colony stimulating factor; IL1RA, IL1 receptor antagonist; IL1RII, IL1 receptor type II; TNF, tumour necrosis factor; SCF, stem cell factor.
IL6, IFNγ and granulocyte macrophage-colony stimulating factor (GM-CSF) and decrease the expression of IL1 and TNFα in women with advanced breast cancer who responded to treatment. Adjuvant and neo-adjuvant treatment of women with breast cancer with paclitaxel also increased serum levels of IL6, IL8 and IL10, and these changes correlated with joint pain and flu-like symptoms. Another anticancer drug, etoposide, has been reported to stimulate production of IL6 by murine macrophages and to induce sickness-like behaviour in animals. Some drugs may increase production of cytokines by the expansion of the particular pool of immune cells, which is also involved in antitumor mechanisms. For example, treatment with gemcitabine increased the numbers of IFNγ-producing T cells and activated CD69+ cells in patients with pancreatic cancer. Chemotherapy may also cause organ-confined toxic effects, which are drug-specific and mediated by cytokines. For example, animal models support a role of increased secretion of TNFα in cisplatin-induced nephrotoxicity. Local production of TNFα by renal parenchymal cells promotes damage and is associated with increased circulating and urinary levels of TNFα. Bleomycin has a major role in treatment of testicular tumours and Hodkin lymphoma but is associated with pulmonary toxicity and occasionally with fatal pulmonary fibrosis. In animal models of bleomycin-induced lung fibrosis, TGFβ1 is a pivotal pro-fibrotic cytokine and other pro-inflammatory cytokines (such as IL1, IL6 and TNFα) also contribute. Aromatase inhibitors, which reduce oestrogen to low levels in the plasma and tissues of postmenopausal women, are used frequently as adjuvant hormonal treatment in postmenopausal women with breast cancer but can cause arthralgia (joint pain) and bone loss, sometimes leading to discontinuation of treatment. In premenopausal women, treatment of cancer can induce premature ovarian failure and significant decreases in oestrogen levels. Various immune cells (such as dendritic cells, macrophages and B cells) express oestrogen receptors and oestrogen can influence their activity. Oestrogen downregulates cell-mediated immune responses and promotes humoral immune responses, whereas oestrogen deficiency increases cell-mediated immune responses and the production of pro-inflammatory cytokines such as IL1, IL6 and TNFα. These cytokines might mediate arthralgia during therapy with aromatase inhibitors. Animal models have shown that TNFα secreted under conditions of oestrogen deficiency directly promotes osteoclast activation and bone resorption. TNFα also augments the sensitivity of maturing osteoclasts to the osteoclastogenic factor RANKL (receptor activator of nuclear factor κB (NFκB) ligand), a member of the TNF superfamily that is produced by activated T lymphocytes, bone marrow stromal cells and osteoblasts.

Various specific cancer treatments stimulate the immune system to produce pro-inflammatory cytokines that are associated with toxic effects of treatment such as cancer-related fatigue, flu-like systemic effects and bone loss; they can lead to impaired quality of life of patients with cancer and poor compliance with treatment. However, stimulation of the immune system by specific cancer treatments might also have a substantial role in producing anticancer effects. Cancer drugs might differentially effect the secretion of cytokines in humans with cancer, and this secretion might be a tool with which to monitor the therapeutic indices of the drugs in the future.

### Cytokines and fatigue, depression and cognitive impairment.

Increasing evidence indicates that 30–60% of people with cancer suffer from fatigue, and that a subset of patients (especially women with breast cancer) suffer from cognitive impairment during and after treatment. Fatigue and cognitive decline have a negative impact on quality of life and such symptoms can persist for at least 10 years in some breast cancer survivors. The underlying mechanisms remain poorly understood, making pharmacological interventions difficult. However, there is evidence that supports increased pro-inflammatory cytokine production as a candidate mechanism for fatigue and cognitive impairment in cancer patients.

Studies in animals have shown that peripheral activation of the immune system by a subseptic dose of LPS induces increased expression of pro-inflammatory cytokines in the brain. Circulating LPS and pro-inflammatory cytokines have been shown to disrupt learning and memory in animals, but peripherally administered LPS in IL6-deficient animals did not result in cognitive defects, indicating the probable importance of IL6 in the development of cognitive impairment. IL10 counteracts the production of IL6 by microglial cells, and IL10-deficient animals show increased production of pro-inflammatory cytokines.
both in the periphery and in the brain that is associated with increased fatigue and motor deficits. Interestingly, increased levels of circulating IL1, TNFα, IL6 and C-reactive protein (CRP) in healthy volunteers challenged by LPS were associated with impaired memory. Increased levels of these cytokines in the elderly have been associated with gradual cognitive decline and development of dementia. Low levels of cytokines and their receptors are produced in the central nervous system (CNS), including areas involved in memory (such as the hippocampus), and animal models have shown that physiological levels of pro-inflammatory cytokines such as IL1 are important for normal memory and neural plasticity.

Higher levels of pro-inflammatory cytokines in the brain are neurotoxic and can induce neurodegenerative disorders in humans. In animals, administration of pro-inflammatory cytokines to the brain was found to cause increased metabolism of neurotransmitters, including noradrenaline, dopamine and serotonin, which are involved in regulation of mood, memory, learning and sleep.

Increased circulating levels of cytokines are known to be associated with cancer and the pathways of communication between CNS and the periphery, including the circulatory system and the peripheral nervous system, are well-understood. However, we have been able to identify only one published clinical study that showed an association between increased circulating levels of cytokines and cognitive impairment. In that study, patients with acute myeloid leukaemia or myelodysplastic syndrome who had higher circulating levels of IL6 at diagnosis were found to have poorer executive function, whereas higher levels of IL8 were associated with better memory. There are no published studies demonstrating a lack of association between cytokines and cognitive impairment, but this may reflect publication bias.

In a quantitative review, a significant correlation between fatigue and circulating levels of IL6 and IL1RA was found in patients with cancer. In breast cancer survivors, persistent fatigue has been associated with increased levels of circulating markers of inflammation including soluble IL6R and IL1RA, increased production of pro-inflammatory cytokines (IL6 and TNFα) by monocytes in response to LPS at rest and in response to experimental challenge, and increased blood levels of CD4+ T cells. Persistent cancer-related fatigue has also been associated with subtle deregulation of the HPA axis with flattened diurnal fluctuation of cortisol levels and blunted cortisol responses to experimental psychological stress. Moreover, a flattened cortisol response during psychological stress was associated with increased production of IL6 by monocytes ex vivo in response to LPS stimulation. Preliminary evidence showing that IL1β –511CC and –511CT genotypes were associated with fatigue in breast cancer survivors (TABLE 5) suggests that the risk of development of cancer-related fatigue might be predetermined. This is further supported by the finding that flattened diurnal fluctuations in cortisol levels have been reported in some healthy individuals. Decreased cortisol production rather than decreased responsiveness of the cortisol receptor appears to have a crucial role in persistent fatigue. In a large and well-designed prospective cohort study, psychological distress and fatigue were related to higher risk of recurrence and decreased survival in women after treatment of early breast cancer, although this is in contrast to previous reports. Some studies of patients with advanced cancer have suggested that distress and depression accelerate disease progression and decrease survival, but many studies in this field suffer from methodological limitations. In humans and animals, distress and depression are associated with impaired cell-mediated immunity and decreased natural killer (NK)-cell activity. In women with breast and ovarian cancer, high levels of psychological distress induce impairment in NK-cell activity peripherally and in the tumour. The flattened diurnal fluctuations of cortisol have been associated with low peripheral NK-cell activity and with poor clinical outcome in a prospective study of women with advanced breast cancer.

Two small clinical studies that examined the use of cytokine antagonists during cancer therapy support a causal role of pro-inflammatory cytokines in cancer-related fatigue. In a small randomized, controlled trial for cancer patients receiving weekly docetaxel (which is known to induce
Reported changes in circulating levels of cytokines:

**IL1RA** and **IL6** are high levels detected in 70%, **IL10** in 8% and **VEGF** in 71% of preoperative levels of **sIL6R** and **TGF** at diagnosis.

Significantly higher levels of **IL6** and **IL10** and lower levels of **IL12** than in healthy controls; higher IL10 levels associated with a higher stage of primary tumour and IL6 burden of metastatic disease than those with lower burden.

Higher levels of **IL6** than in healthy controls.

**Type of cancer**

<table>
<thead>
<tr>
<th>Type of cancer</th>
<th>n (setting)</th>
<th>Reported changes in circulating levels of cytokines</th>
<th>Prognostic significance</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soft-tissue sarcoma</td>
<td>145 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL1RA</strong>, <strong>sIL2R</strong>, <strong>IL6</strong>, <strong>IL8</strong>, <strong>IL10</strong>, <strong>TNFRI</strong>, <strong>TNFRII</strong>, <strong>TNFα</strong>, <strong>M-CSF</strong>, <strong>FGF2</strong> and <strong>VEGF</strong> than controls</td>
<td>No</td>
<td>19</td>
</tr>
<tr>
<td>Adult bone sarcoma</td>
<td>72 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong>, <strong>IL8</strong>, <strong>L10</strong>, <strong>VEGF</strong>, <strong>FGF2</strong>, <strong>M-CSF</strong>, <strong>IL1RA</strong>, <strong>TNFRI</strong> and <strong>TNFRII</strong> than healthy controls; significantly higher levels of <strong>IL6</strong>, <strong>IL8</strong>, <strong>IL1RA</strong>, <strong>TNFRI</strong> and <strong>M-CSF</strong> than in patients with benign bone tumours</td>
<td>Higher levels of <strong>IL1RA</strong> and <strong>TNFRI</strong> are an independent predictor of shorter OS</td>
<td>20</td>
</tr>
<tr>
<td>Breast cancer</td>
<td>111 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong> than in healthy controls</td>
<td>NA</td>
<td>21</td>
</tr>
<tr>
<td></td>
<td>45 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong>, <strong>IL8</strong> and <strong>IL10</strong> than in healthy controls. Patients with higher stages (stage III and IV) had higher levels of cytokines compared with patients with stage II</td>
<td>NA</td>
<td>209</td>
</tr>
<tr>
<td></td>
<td>96 (progressive metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong> in patients with higher burden of metastatic disease than those with lower burden</td>
<td>Higher levels of <strong>IL6</strong> are associated with shorter OS</td>
<td>206</td>
</tr>
<tr>
<td></td>
<td>65 (recurrent)</td>
<td>Significantly increased levels of <strong>IL6</strong> in people with recurrent breast cancer compared with non-recurrent breast cancer</td>
<td>NA</td>
<td>210</td>
</tr>
<tr>
<td></td>
<td>77 (metastatic)</td>
<td>Significantly higher levels of <strong>IL8</strong> in non-metastatic and metastatic disease compared with healthy controls, and in metastatic disease as compared with non-metastatic disease</td>
<td>Higher levels of <strong>IL8</strong> are an independent predictor of shorter OS in women with metastatic disease</td>
<td>22</td>
</tr>
<tr>
<td>Pancreatic cancer</td>
<td>51 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong>, <strong>IL8</strong>, <strong>IL10</strong> and <strong>IL1RA</strong> than in healthy controls</td>
<td>High levels of <strong>IL6</strong> are an independent predictor of shorter OS</td>
<td>23</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>155 (non-metastatic)</td>
<td>Higher levels of <strong>IL6</strong> than in healthy controls</td>
<td>Higher levels of <strong>IL6</strong> are an independent predictor of shorter OS</td>
<td>24</td>
</tr>
<tr>
<td>Kidney cancer</td>
<td>64 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong> and <strong>IL10</strong> than in patients with benign disease at diagnosis and 3 months after resection of the primary tumour</td>
<td>NA</td>
<td>25</td>
</tr>
<tr>
<td></td>
<td>138 (metastatic)</td>
<td><strong>IL6</strong> detectable in 70%, <strong>IL10</strong> in 8% and <strong>VEGF</strong> in 71% of patients, respectively</td>
<td>Higher levels of <strong>IL6</strong> are an independent predictor of shorter PFS and OS</td>
<td>207</td>
</tr>
<tr>
<td>Prostate cancer</td>
<td>423 (non-metastatic)</td>
<td>Not reported</td>
<td>Preoperative levels of <strong>sIL6R</strong> and <strong>TGFβα</strong> increased the accuracy of classical nomogram to predict biochemical recurrence</td>
<td>208</td>
</tr>
<tr>
<td>Head and neck cancer</td>
<td>40 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong> and <strong>IL8</strong> than in healthy controls</td>
<td>NA</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>11 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong>, <strong>IL8</strong> and <strong>VEGF</strong> than in healthy controls and patients with laryngeal papilloma</td>
<td>NA</td>
<td>243</td>
</tr>
<tr>
<td></td>
<td>58 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL6</strong> and <strong>IL10</strong> and lower levels of <strong>IL12</strong> in patients with higher tumour and node stage of primary tumour</td>
<td>NA</td>
<td>211</td>
</tr>
<tr>
<td></td>
<td>57 (non-metastatic)</td>
<td>Significantly higher levels of <strong>IL10</strong> and lower levels of <strong>IL12</strong> than in healthy controls; higher IL10 levels associated with higher tumour stage</td>
<td>NA</td>
<td>27</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>519 (at diagnosis)</td>
<td>Not reported</td>
<td>High levels of <strong>IL1RA</strong> and <strong>IL6</strong> are an independent predictor of shorter EFS</td>
<td>244</td>
</tr>
<tr>
<td>AML, MDS</td>
<td>198 (at diagnosis)</td>
<td>Significantly increased levels of <strong>TNFα</strong>, <strong>IL1RA</strong>, <strong>IL6</strong> and <strong>IL10</strong> than in healthy controls</td>
<td>Higher levels of <strong>TNFα</strong> was associated with lower CR rate, EFS and OS (not an independent prognostic factor)</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td>54 (at diagnosis)</td>
<td>Significantly higher levels of <strong>IL1</strong>, <strong>IL1RA</strong>, <strong>IL6</strong>, <strong>IL8</strong> and <strong>TNFα</strong> than in healthy controls</td>
<td>NA</td>
<td>109</td>
</tr>
</tbody>
</table>

Asterisk: **AML**, acute myeloid leukemia; **CR**, complete remission; **EFS**, event-free survival; **FGF2**, fibroblast growth factor 2; **IL**, interleukin; **IL1RA**, IL1 receptor antagonist; **M-CSF**, macrophage-colony stimulating factor; **MDS**, myelodysplastic syndrome; **NA**, not assessed; **NS**, not stated; **OS**, overall survival; **PFS**, progression-free survival; **sIL2R**, soluble IL2R; **TNF**, tumour necrosis factor; **TNFR**, TNF receptor; **VEGF**, vascular endothelial growth factor.
Table 3 | Genetic polymorphisms of cytokine genes associated with cancer

<table>
<thead>
<tr>
<th>Association</th>
<th>n</th>
<th>Cytokine</th>
<th>Genotype, allele or haplotype</th>
<th>Association</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Susceptibility to cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NHL, and breast, endometrial, prostate and lung cancer</td>
<td>124; 41; 202</td>
<td>TNFα</td>
<td>–308 A</td>
<td>Increased susceptibility</td>
<td>33–35</td>
</tr>
<tr>
<td>Lung, gastric, uterine, renal and colorectal cancer</td>
<td>202; 169</td>
<td>TNFα</td>
<td>–238 A</td>
<td>Decreased susceptibility</td>
<td>35,36</td>
</tr>
<tr>
<td>Gastric cancer</td>
<td>366; 152</td>
<td>IL1β</td>
<td>–238 A</td>
<td>Increased susceptibility</td>
<td>38,39</td>
</tr>
<tr>
<td>Diffuse large B-cell NHL (pooled analysis)</td>
<td>3,586</td>
<td>TNFα</td>
<td>–308 A, –3575 A</td>
<td>Increased susceptibility</td>
<td>37</td>
</tr>
<tr>
<td>Melanoma, non-cardia gastric and renal cancer (systematic review)</td>
<td>6,747</td>
<td>IL10</td>
<td>ATA (–1082 A, –819 T, –592 A)</td>
<td>Increased susceptibility</td>
<td>32</td>
</tr>
<tr>
<td>Cervical cancer, cardia gastric cancer, HCC, SCC of skin (post-transplant) and multiple myeloma</td>
<td>IL10</td>
<td>GCC (–1082 G, –819 C, –592 C); ACCT (–1082 A, –819 C, –592 C)</td>
<td>IL10R 112/114 microsatellites</td>
<td>Increased susceptibility</td>
<td></td>
</tr>
<tr>
<td><strong>Cancer cachexia</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gastric cancer (USA population)</td>
<td>44</td>
<td>IL1β</td>
<td>+3954 CT or +3954 TT (presence of T allele)</td>
<td>Decreased cachexia</td>
<td>173</td>
</tr>
<tr>
<td>Gastric cancer (Chinese population)</td>
<td>214</td>
<td>IL1β</td>
<td>+3954 T</td>
<td>Increased cachexia</td>
<td>174</td>
</tr>
<tr>
<td><strong>Cancer-related fatigue</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer survivors</td>
<td>33</td>
<td>IL1β</td>
<td>–511CC, –511CT (presence of C allele)</td>
<td>Increased fatigue</td>
<td>116</td>
</tr>
<tr>
<td><strong>Cancer pain</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NSCLC</td>
<td>606</td>
<td>IL8</td>
<td>–251 TA, –251 AA (presence of A allele)</td>
<td>Increased pain</td>
<td>245</td>
</tr>
<tr>
<td><strong>Prognosis of cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal cancer (advanced disease)</td>
<td>80</td>
<td>IL4</td>
<td>–589 T, –33 T</td>
<td>Decreased survival</td>
<td>214</td>
</tr>
<tr>
<td>Melanoma (advanced disease)</td>
<td>108</td>
<td>IL10</td>
<td>ATA (–1082 A, –819 T, –592 A)</td>
<td>Increased survival</td>
<td>215</td>
</tr>
<tr>
<td>T-cell NHL</td>
<td>108</td>
<td>IL10</td>
<td>ATA (–1082 A, –819 T, –592 A)</td>
<td>Increased survival</td>
<td>216</td>
</tr>
<tr>
<td>Diffuse large B-cell NHL</td>
<td>199</td>
<td>IL10</td>
<td>–1082 GG, –1082 AG (presence of G allele)</td>
<td>Increased survival</td>
<td>217</td>
</tr>
<tr>
<td><strong>Toxicity of cancer therapy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Breast cancer, gynaecological cancers</td>
<td>15; 26; 38; 25</td>
<td>TGFβ</td>
<td>–509 T</td>
<td>Increased risk of radiation fibrosis</td>
<td>59–62</td>
</tr>
</tbody>
</table>

HCC, hepatocellular cancer; IL, interleukin; IL1RA, IL1 receptor antagonist; NHL, non-Hodgkin lymphoma; NSCLC, non-small-cell lung cancer; SCC, squamous cell cancer; TGFβ, transforming growth factor-β; TNFα, tumour necrosis factor-α.

fatigue) with or without etanercept, a TNFα decoy receptor, patients had significantly less fatigue and could receive higher doses of docetaxel than those who received docetaxel alone. In a prospective study of patients with Castleman disease, which is a lymphoproliferative disorder characterized by increased production of IL6, administration of a monoclonal antibody against IL6R was strongly associated with reduced fatigue. Also, in three randomized, placebo-controlled clinical trials of adalimumab, a monoclonal antibody against TNFα, patients with uncontrolled rheumatoid arthritis receiving adalimumab in combination with methotrexate or other standard therapy had significantly less fatigue than those receiving methotrexate or standard therapy alone.

Brain imaging studies indirectly support an association between cytokines, chemotherapy and cognitive impairment. In a recent study, treatment of patients with hepatitis C using IFNαx was associated with impaired cognitive function, which correlated with higher brain activity than healthy controls in the dorsal part of the anterior cingulated cortex during a task of visuospatial attention, as documented by functional magnetic resonance imaging scans. Functional imaging of the brain has shown similar changes in people with cancer who received chemotherapy. For example, 5–10 years after treatment breast cancer survivors who received chemotherapy had higher activity in the lower frontal gyrus, as revealed by functional positron-emission tomography, than breast cancer survivors who were not treated with chemotherapy.

Cytokines and physical activity. There is strong evidence from randomized, controlled trials that aerobic physical activity is able to reduce cancer fatigue, but the underlying mechanisms are unknown. However, there is emerging data indicating that a physically active lifestyle modulates cytokine production and is associated with anti-inflammatory effects. In people with chronic conditions such as obesity, heart failure and metabolic syndromes, which are characterized by increased circulating pro-inflammatory cytokines and other inflammatory markers, intervention studies of chronic physical activity alone or in combination with diet showed reductions in the levels of circulating IL6 and/or TNFα in some but not all studies. Evidence from studies with healthy humans and animals shows that increased
levels of circulating IL6, which is released intermittently from skeletal muscle during periods of intense physical activity, has strong anti-inflammatory effects due to inhibition of TNFα production and induction of IL10 and IL1RA production141. However, this mechanism cannot explain the beneficial effect of exercise on fatigue in people with cancer, especially advanced cancer where less intensive physical activity is beneficial. Studies in people who did not have cancer showed that exercise reduces expression of TLR4 by peripheral innate immune cells and is associated with blunted TLR signalling and lower production of IL1β, IL6 and TNFα142. Studies in humans and animals suggest that physical activity is important for the health of the brain and causes structural and functional changes. This may occur either directly by induction of central and peripheral growth factors such as insulin-like growth factor 1 (IGF1), brain-derived neurotrophic factor (BDNF) and vascular endothelial growth factor (VEGF, also known as VEGFA) or indirectly by reducing the activity of pro-inflammatory cytokines that inhibit signalling by these growth factors143. These findings further support the involvement of cytokines in cancer-related fatigue, cognitive impairment and the beneficial effects of physical activity.

**Cytokines and stress.** Cancer poses numerous physical and psychological stresses. Many cancer patients, during both treatment and long-term follow-up, experience psychological distress including anxiety and depression144. In animals, stress can activate pro-inflammatory pathways in the brain by activation of microglial cells145,146 (FIG. 2), and these cells respond in a heightened fashion when exposed to LPS, either centrally in the brain147 or peripherally148. In humans, modulation of the immune system by stress is well-known149. Studies of chronic and acute stress in models of human stress showed increased circulating levels of IL6 and TNFα compared with controls146,147. In stress-related neuropsychiatric disorders there is evidence of abnormal glucocorticoid signalling150, and this may occur in people with cancer. In general, depressed patients have an activated HPA axis, increased levels of cortisol and increased circulating levels of several pro-inflammatory cytokines, which can further stimulate the HPA axis and cortisol production154. In people with depression there is evidence of malfunction of cortisol receptors leading to cytokine-induced cortisol resistance, impaired feedback inhibition of the HPA axis and sustained activation of immune cells153,155. Depression and psychological distress sensitize and enhance inflammatory responses to subsequent stressful events and to challenge with various antigens150. In animal models and in vitro studies, several classes of antidepressants have been shown to reduce pretreatment levels of pro-inflammatory cytokines, such as IFNγ and TNFα, and to increase the production of anti-inflammatory cytokines, such as IL10. Indeed, antidepressant treatment can lead to normalization of circulating cytokine production in people with depression156.

Cancer patients who are clinically depressed have significantly higher levels of circulating IL6 than non-depressed cancer patients or healthy controls157,158. In observational studies of breast cancer survivors several years after diagnosis, cancer-related fatigue was strongly associated with depressed mood160, supporting a common underlying mechanism. In cancer patients undergoing cytokine therapy with IL2 or IFNα, depression was related to decreased levels of circulating tryptophan, a precursor of serotonin, and consequently to decreased availability of serotonin in the brain159. Indeed, peripheral pro-inflammatory cytokines can induce sickness behaviour and depression in animals by decreasing the availability of serotonin in the brain162.

Despite the association between depression and cancer-related fatigue, therapy with the selective serotonin-reuptake inhibitor paroxetine, which increases synaptic levels of serotonin in the brain, has been found to reduce depression but not fatigue in patients with cancer-receiving chemotherapy161,162.
Cytokines in cancer. Tumour and immune cells are sources of cytokines, which support the growth of cancer and lead to psychobehavioural symptoms (fatigue, depression, and cognitive impairment), drug toxicity, drug resistance, anorexia and cachexia, pain, and cancer recurrence and progression. Genetic background, cancer treatment and psychological distress may corroborate the production of cytokines. In cancer survivors, hyperactive immune cells might be the major source of cytokines in psychobehavioural symptoms.

Suggesting that modulation of serotonin may not be a primary mechanism of fatigue related to cancer. Chronic fatigue might be explained by persistent effects of pro-inflammatory cytokines in the brain and peripheral tissues that are not adequately counterbalanced by anti-inflammatory mechanisms.

Cancer-related fatigue, depression and cognitive impairment usually lead to a sedentary lifestyle, resulting in pro-inflammatory effects and increased cytokine production that may further sustain these disturbing symptoms. Cytokines are challenging candidate factors in psychobehavioural symptoms (fatigue, cognitive impairment and depression) that need further research.

Cytokines and anorexia and cachexia. Anorexia and cachexia occur commonly in patients with some types of cancer such as lung or pancreas, but rarely in those with others such as breast or prostate cancer. Anorexia and cachexia in people with advanced cancer are characterized by breakdown of skeletal muscle and abnormalities in fat and carbohydrate metabolism despite adequate nutritional intake, and are not related simply to burden of disease. Cachectic cancer patients have lower survival rates than patients without significant weight loss.

Support for a role for pro-inflammatory cytokines in the induction of cachexia comes from animal studies, with supporting evidence in humans. Increased levels of IL1 in the brain have been associated with anorexia in animals, and pro-inflammatory cytokines may be involved in the development both of anorexia and cachexia and of depression (which frequently coexist) through a common pathway. In particular, TNFα induces proteolysis of skeletal muscle and increased expression of genes that encode enzymes in the ubiquitin-dependent proteolytic pathway in cancer patients. TNFα also induces uncoupling of mitochondrial respiration and metabolic energy production in animal models. Such molecular changes, including increased activity of muscle ubiquitin proteasome, may be detectable before weight loss, but a small double-blinded, placebo-controlled trial of etanercept did not show benefit in weight, appetite or survival in patients with advanced solid cancers. A possible explanation is the involvement of multiple cytokines in causing the anorexia and cachexia syndrome in cancer patients.

A recent exploratory analysis of the effect of IL1β polymorphisms on cachexia in patients in the United States with advanced gastric cancer suggested a significant association between IL1β (−31 C/T and T/T) genotypes and diminished appetite — the IL1β (+3,954 C/T and T/T) genotypes were associated with greater improvements in weight and survival than the IL1β (+3,954 C/C) genotype, independent of treatment effect. A similar study in Chinese patients with locally advanced gastric cancer showed a converse association between the IL1β (+3,954 T) allele and cachexia (TABLE 5). These conflicting results, which are commonly seen in candidate gene studies, might also be explained by the different genetic backgrounds of Western and Asian populations, the interplay between different genetic polymorphisms of the same cytokine and interactions between different cytokines.

Cytokines and pain. Cytokine activation and deregulation is recognized in a variety of painful disease states. Neuropathic pain in cancer is common, the major causes being some types of anticancer treatment and the direct infiltration of nerves by cancer cells. In numerous animal studies expression of IL1, IL6 and TNFα is upregulated in peripheral nerves, the spinal cord and in particular regions of the brain after peripheral nerve injury. By contrast, anti-inflammatory cytokines (IL4 and IL10) and neutralizing antibodies against pro-inflammatory cytokines or their receptors promote analgesia. Intrathecal injection of IL1RA or of a vector incorporating IL10 decreased production of pro-inflammatory cytokines in the spinal cord and attenuated neuropathic pain. In a study of patients with a variety of pain-associated peripheral neuropathies, levels of circulating pro-inflammatory and anti-inflammatory cytokines were significantly increased and decreased, respectively, compared with patients with painless neuropathies or healthy controls. Shifting the balance from pro- to anti-inflammatory cytokines is a promising approach to management of neuropathic cancer pain.

The release of pro-inflammatory cytokines by peripheral immune cells during inflammation, infection or trauma leads to release of pro-inflammatory cytokines by glia in the CNS; these cytokines are associated with induction and maintenance of pain. Studies in animals and humans show that morphine induces secretion of pro-inflammatory cytokines by glial cells, leading to suppression of acute opioid analgesia, induction of tolerance, development of opioid dependence and the seemingly paradoxical withdrawal-induced enhancement of pain. Preoperative use of pentoxifylline, an inhibitor of cytokine production in immune cells, attenuated release of pro-inflammatory cytokines and reduced morphine consumption after surgery in patients with colorectal cancer. The development of interventions that suppress opioid-induced activity of glial cells might promote better analgesia and enable more effective and safer use of these drugs.
Cytokines and patient outcome

Cytokines, drug toxicity and drug resistance. Most anticancer drugs are metabolized in the liver by cytochrome P450 (CYP) enzymes with the isoenzyme CYP3A4 being most important in this process.\(^\text{196}\) Clinical studies have confirmed a relationship between pro-inflammatory cytokines and a systemic inflammatory response with increased levels of CRP, decreased activity of CYP enzymes\(^\text{184,185}\) and increased toxicity of chemotherapy\(^\text{196}\) (FIG. 3). However, the effect of the cancer on the inhibition of CYP enzymes was not studied. Recently, a mechanistic link between IL6 (which is associated with an acute-phase response induced by cancer growth) and impaired hepatic drug metabolism was demonstrated in a transgenic animal model that recreates most aspects of human CYP3A4 regulation\(^\text{197}\).

Although increased levels of pro-inflammatory cytokines can cause impaired metabolism and clearance of anticancer drugs, they may also reduce the anticancer effectiveness of the drugs (FIG. 3). Pro-inflammatory cytokines can lead to activation of NFκB (BOX 1), which enables survival of cancer cells and provides a mechanism by which they might become resistant to chemotherapy and radiotherapy. By contrast, inhibitors of NFκB can sensitize tumour cells to the apoptosis that is induced by chemotherapeutic agents\(^\text{188}\). For example, in human cell lines derived from hormone-refractory prostate cancer, higher activity of NFκB and increased production of IL6 were associated with decreased sensitivity to docetaxel, whereas an NFκB inhibitor decreased production of IL6 and reversed resistance to docetaxel. In the same study, increased circulating levels of IL6 before treatment correlated with less of a decrease in the circulating levels of prostate-specific antigen\(^\text{189}\). Clinical studies in other cancers have confirmed an association between circulating levels of IL6 and resistance to chemotherapy\(^\text{190,191}\).

Prognostic value of cytokines. There is increasing evidence that the pattern and level of cytokine production is related to cancer prognosis. Genes associated with metastasis can be expressed in cancer and stromal cells in early-stage primary tumours\(^\text{192–194}\), and tumour infiltration by some innate immune cells, such as mast cells and macrophages, has been reported to be detrimental in different human cancers\(^\text{195–198}\). Increased expression of the gene encoding CD68, a macrophage marker, was associated with poor prognosis when used as a part of a 21-gene signature (Oncotype DX) in breast cancer\(^\text{199}\). A gene expression signature of 17 mainly cytokine-encoding genes isolated from non-cancerous liver tissue surrounding hepatocellular carcinoma, indicated that a switch from expression of T\(_1\), To T\(_2\) cytokines independently predicted tumour metastasis and recurrence\(^\text{200}\). Similarly, a 15-cytokine gene signature in non-cancerous lung tissue with a shift towards T\(_2\) cytokines predicted the involvement of regional lymph nodes in patients with adenocarcinoma of the lung, whereas a refined 11-cytokine gene signature from lung tumours and non-cancerous surrounding tissue independently predicted survival in early stage adenocarcinoma of the lung\(^\text{201}\). These findings support the hypotheses that cancer and stromal cells collaborate with surrounding unininvolved tissue in cancer development. Cytokine gene signatures of the non-cancerous surrounding tissue combined with gene signatures of the primary tumour can refine prognostic information for cancer recurrence and provide new insights into the biology of cancer.

The genes that encode IL1, IL6, TNFα and TGFβ are expressed in metastases from several cancer types, suggesting that common transcriptional programmes are activated during invasion\(^\text{202}\). There is evidence from animal models that risk of metastatic dissemination is dependent on the germline genetic background, which contrasts with the conventional model in which somatic mutations in cancer cells create a subgroup of cells that disseminate\(^\text{203}\). In patients with early-stage colorectal cancer, high levels of IL6 secretion by peripheral blood mononuclear cells stimulated in vitro by LPS independently predicted for metastatic disease and impaired survival, although some healthy controls were also high producers of IL6 (REF. 204). These results suggest that host factors may have a major role in the progression of cancer.

IL6 is one of the most ubiquitously deregulated cytokines in cancer patients\(^\text{205}\) and high levels of circulating IL6 most commonly predicted poor outcome in observational studies\(^\text{23,24,206–208}\) (TABLE 2). Other data suggest that some specific cytokines and their receptors might have a predictive role for outcome in some cancer types\(^\text{209,210,211}\). Stage is an important prognostic factor in every cancer type and in observational studies there is a consistent trend of higher levels of circulating cytokines in more advanced stages of various cancers than in early stages\(^\text{22,24,27,208,209–211}\) (TABLE 2), which further supports an association with outcome of cancer.

Genetic polymorphisms of cytokines might also affect outcome (TABLE 3). In a study of patients with advanced renal cancer, the presence of the IL4 (–589 T, –33 T) haplotype, which is associated with increased expression of this T\(_2\) cytokine\(^\text{212,213}\), was an independent prognostic factor for lower survival than that of patients that were homozygous for IL4 (–589 C, –33 C)\(^\text{214}\). However, the same IL4 haplotype (–589 T, –33 T) decreased susceptibility for the development of renal cancer\(^\text{215}\). Similarly, the ATA (–1082 A, –819 T, –592 A) haplotype of IL10, which is associated with low production of IL10, independently predicted increased survival in patients with advanced melanoma (but also increased susceptibility for the development of melanoma)\(^\text{215}\) and T-cell non-Hodgkin lymphoma\(^\text{216}\). By contrast, the IL10 (–1082 G) allele, which results in increased secretion of IL10, independently predicted improved survival of patients with diffuse large B-cell lymphoma\(^\text{217}\). Thus, cytokines may have various roles in different stages of cancer and in different cancer types.

Diet, exercise and cytokine levels. Increasing evidence from observational studies indicates that better lifestyle, including moderately intense physical activity\(^\text{218–221}\) and lower fat intake\(^\text{218–221}\), results in improved survival after treatment of patients with early breast and colon cancer. In women with breast cancer, beneficial effects of better lifestyle seem to be stronger in oestrogen receptor (ER)-positive disease\(^\text{218–220}\). By contrast, in the Women’s Intervention Nutrition Study, a large randomized trial that investigated lifestyle intervention with reduced dietary fat intake, there was a decreased probability of breast cancer recurrence, especially in women with ER-negative breast cancers\(^\text{222}\), indicating involvement of mechanisms other than changes in female sex hormones. In the Million Women Study, higher body mass index was associated with an increased risk for 10 of 17 different cancers and the patterns for cancer mortality were broadly similar to those for cancer incidence\(^\text{219}\). The anti-inflammatory effect of physical activity, and the attenuation of inflammation that results from lower fat content in the body, could explain the better outcome of cancer in these studies. A physically active lifestyle leads to reduced TLR4 signalling and decreased production of pro-inflammatory cytokines in non-cancer populations\(^\text{223}\) and has been reported to increase cytotoxic activity of NK cells in breast cancer survivors\(^\text{226}\). White adipose tissue is a source of various cytokines (that is, adipokines) with predominantly anti-inflammatory activity\(^\text{227}\). The increased production of cytokines by adipocytes and
macrophages that infiltrate adipose tissue is reduced by physical activity and by a hypo-caloric diet. The effect of physical activity and other lifestyle interventions on cancer outcome might depend on genetically pre-determined ability to produce cytokines and other mediators, such that only a subset of patients might benefit from such activity.

Concluding remarks
Pro-inflammatory cytokines are involved in the development and progression of cancer and are also associated with fatigue, depression, cognitive impairment, cachexia and anorexia, and pain, which affect quality of life. Sustained production of some cytokines may also be associated with cancer recurrence and progression. Strategies to inhibit the effects of such cytokines might therefore have a profound effect on quality of life and survival. Given the pleiotropic and redundant nature of cytokines, a successful approach might not involve inhibition of one particular cytokine but rather aim to shift the balance between pro- and anti-inflammatory cytokines. Increasing evidence suggests that, with its anti-inflammatory effects, physical activity might be an important part of treatment with the goals of prevention of fatigue and even prevention of cancer recurrence and death. There is a signal from candidate gene studies that polymorphisms in cytokine genes influence the susceptibility and course of cancer, and the symptoms related to cancer and its treatment.

Bostjan Seraga and Ian F. Tannock are at the Division of Medical Oncology, Princess Margaret Hospital, Halbo Zhang is at the Departments of Anesthesiology and Critical Care Medicine, St. Michael’s Hospital, and Lorri J. Bernstein is at the Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, University of Toronto, Toronto, Canada.

Correspondence to I.F.T.
E-mail: ian.tannock@uhn.on.ca
doi: 10.1038/jnccr.2007.157
Published online 10 October 2008
Severely damaged normal organs are particularly sensitive to chemotherapeutic injury. Cytotoxic drugs that do not target neoplastic cells can cause serious and irreversible damage to the lung, heart, kidney, and liver. These effects are dose-related and may limit the therapeutic index of the chemotherapeutic agents employed.

The cardiac toxicity associated with chemotherapeutic agents is observed less commonly than chemotherapy-induced cardiomyopathy. Cardiotoxic effects are produced by drugs that damage the myocytes or stimulate the immune system to attack cardiac myocytes. These toxic effects result from chemotherapeutic drugs that reduce cardiac myocyte contractility, provoke fibrosis and other cardiac structural changes, or lead to increased cardiac myocyte apoptosis.

The mechanisms of chemotherapy-induced cardiotoxicity can be grouped into three general categories: 1) cardiotoxicity induced by chemotherapeutic agents, 2) cytokine-mediated injury, and 3) immune-mediated injury caused by the host response to tumors and chemotherapeutic agents. Cardiotoxicity induced by chemotherapeutic agents includes those produced by doxorubicin, bleomycin, mitomycin C, and cisplatin. Mitomycin C and doxorubicin are DNA intercalators that interact with DNA and produce DNA damage that can result in cell death. Doxorubicin can also produce cardiotoxicity via apoptosis and necrosis. Cisplatin-induced cardiotoxicity is mediated by tumor necrosis factor (TNF) and other cytokines and chemokines, and the ensuing chemotherapeutic injury.

Doxorubicin-induced cardiomyopathy can be prevented by the concurrent use of the antibiotic daunorubicin, a structurally related but more nephrotoxic anthracycline. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor (TNF)-α, which stimulates the release of IL-6, IL-1, TNF, and IL-8.

In the late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genetic causes. Br J Cancer 96, 1001–1007 (2002).


[The rest of the text is not relevant to the content and is omitted for brevity.]


